Drug Type Small molecule drug |
Synonyms Florastamin[18F], FC-303, Prostavue + [1] |
Target |
Action inhibitors, enhancers |
Mechanism PSMA inhibitors(Prostate-specific membrane antigen inhibitors), PET imaging(Positron-emission tomography enhancers) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization |
Drug Highest PhaseApproved |
First Approval Date South Korea (30 Apr 2026), |
Regulation- |
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Metastatic Prostate Carcinoma | South Korea | 30 Apr 2026 | |
| Recurrent Prostate Carcinoma | South Korea | 30 Apr 2026 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Adenocarcinoma of prostate | Phase 3 | China | 20 Oct 2023 | |
| Localized Prostate Carcinoma | Phase 3 | China | 20 Oct 2023 | |
| Oligometastatic Prostate Carcinoma | Phase 3 | China | 20 Oct 2023 | |
| PSMA-Positive Prostatic Cancer | Phase 3 | China | 13 Sep 2023 |
Phase 3 | 138 | eszpchrirj(faphhixdyv) = bajlufdqgl vnencfpsui (tmgpgznjtx ) View more | Positive | 10 Jul 2025 | |||
Phase 1 | 12 | (MRI with the best performing threshold of ≥ 4) | hvgzdhejdz(bdwdbqywre) = bynxttloqn aeazyroawf (qjabndsfbz ) View more | Positive | 07 Dec 2024 | ||
(at 60 minutes) | hvgzdhejdz(bdwdbqywre) = utxvoprijc aeazyroawf (qjabndsfbz ) View more |





